Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$0.57 USD
+0.04 (7.15%)
Updated Jul 3, 2024 12:59 PM ET
After-Market: $0.56 -0.01 (-0.88%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
SPRB 0.57 +0.04(7.15%)
Will SPRB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SPRB
Spruce Biosciences, Inc. (SPRB) Reports Q1 Loss, Tops Revenue Estimates
Pfizer (PFE) Q1 Earnings and Revenues Beat Estimates
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
Other News for SPRB
Spruce Biosciences price target lowered by $1 at Oppenheimer, here's why
Spruce Biosciences Recognized as a Bay Area Best Place to Work
Analysts Conflicted on These Healthcare Names: Tyra Bioscience (TYRA), Spruce Biosciences (SPRB) and UnitedHealth (UNH)
H.C. Wainwright Remains a Hold on Spruce Biosciences (SPRB)
Buy Rating Affirmed: Strategic Partnerships and Promising Trials Drive Optimism for Spruce Biosciences